161 related articles for article (PubMed ID: 36611001)
1. Potential Impact of Pharmacogenomic Single Nucleotide Variants in a Rural Caucasian Population.
Williams GR; Tsongalis GJ; Lewis LD; Barney RE; Cook LJ; Aaron Geno K; Nerenz RD
J Appl Lab Med; 2023 Mar; 8(2):251-263. PubMed ID: 36611001
[TBL] [Abstract][Full Text] [Related]
2. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic profile of a central European urban random population-Czech population.
Proietti R; Maranho Neto GA; Kunzova S; Lo Re O; Ahola-Olli A; Heliste J; Gonzalez-Rivas JP; Vinciguerra M
PLoS One; 2023; 18(4):e0284386. PubMed ID: 37079615
[TBL] [Abstract][Full Text] [Related]
5. Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing?
Lopes JL; Harris K; Karow MB; Peterson SE; Kluge ML; Kotzer KE; Lopes GS; Larson NB; Bielinski SJ; Scherer SE; Wang L; Weinshilboum RM; Black JL; Moyer AM
J Mol Diagn; 2022 Mar; 24(3):253-261. PubMed ID: 35041929
[TBL] [Abstract][Full Text] [Related]
6. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.
Ragia G; Karantza IM; Kelli-Kota E; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
Drug Metab Pers Ther; 2017 Dec; 32(4):183-190. PubMed ID: 29252193
[TBL] [Abstract][Full Text] [Related]
7. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
[TBL] [Abstract][Full Text] [Related]
8. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
[TBL] [Abstract][Full Text] [Related]
9. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
Reizine NM; Danahey K; Truong TM; George D; House LK; Karrison TG; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
Cancer; 2022 Apr; 128(8):1649-1657. PubMed ID: 35090043
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of pharmacogenetic variants of vitamin K epoxide reductase complex subunit 1 gene (rs9923231), cytochrome P450 family 2 subfamily C member 9 gene (rs1799853) and cytochrome P450 family 3 subfamily-A member-5 gene (rs776746) among 13 ethnic groups of Pakistan.
Firasat S; Raza A; Khan AR; Abid A
Mol Biol Rep; 2023 May; 50(5):4017-4027. PubMed ID: 36849858
[TBL] [Abstract][Full Text] [Related]
11. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
[TBL] [Abstract][Full Text] [Related]
12. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.
Chanfreau-Coffinier C; Hull LE; Lynch JA; DuVall SL; Damrauer SM; Cunningham FE; Voight BF; Matheny ME; Oslin DW; Icardi MS; Tuteja S
JAMA Netw Open; 2019 Jun; 2(6):e195345. PubMed ID: 31173123
[TBL] [Abstract][Full Text] [Related]
13. Clinical Utility and Economic Impact of CYP2D6 Genotyping.
Reynolds KK; McNally BA; Linder MW
Clin Lab Med; 2016 Sep; 36(3):525-42. PubMed ID: 27514466
[TBL] [Abstract][Full Text] [Related]
14. Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.
Saito R; Takeda K; Yamamoto K; Nakagawa A; Aoki H; Fujibayashi K; Wakasa M; Motoyama A; Iwadare M; Ishida R; Fujioka N; Tsuchiya T; Akao H; Kawai Y; Kitayama M; Kajinami K
J Thromb Thrombolysis; 2014 Jul; 38(1):105-14. PubMed ID: 23928870
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
Kirchheiner J; Seeringer A
Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
[TBL] [Abstract][Full Text] [Related]
16. [Establishment of a pharmacogenomic testing system for the realization of individual pharmacotherapy].
Yokota H; Satoh Y; Ono Y; Kaneko M; Ikeda H; Tsuji S; Yatomi Y
Rinsho Byori; 2008 Sep; 56(9):772-80. PubMed ID: 18975556
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
18. Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations.
Bonifaz-Peña V; Contreras AV; Struchiner CJ; Roela RA; Furuya-Mazzotti TK; Chammas R; Rangel-Escareño C; Uribe-Figueroa L; Gómez-Vázquez MJ; McLeod HL; Hidalgo-Miranda A; Parra EJ; Fernández-López JC; Suarez-Kurtz G
PLoS One; 2014; 9(11):e112640. PubMed ID: 25419701
[TBL] [Abstract][Full Text] [Related]
19. The role of pharmacogenomics in adverse drug reactions.
Cacabelos R; Cacabelos N; Carril JC
Expert Rev Clin Pharmacol; 2019 May; 12(5):407-442. PubMed ID: 30916581
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]